Regenxbio Q1 2024 Earnings Preview
Seeking Alpha News (Tue, 7-May 5:20 PM ET)
PRNewswire (Wed, 1-May 7:05 AM ET)
PRNewswire (Wed, 24-Apr 7:05 AM ET)
PRNewswire (Thu, 28-Mar 7:05 AM ET)
REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days
PRNewswire (Wed, 27-Mar 4:05 PM ET)
REGENXBIO to Participate in Upcoming Investor Conferences
PRNewswire (Mon, 11-Mar 7:05 AM ET)
REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants
PRNewswire (Wed, 6-Mar 11:21 PM ET)
REGENXBIO Announces Proposed Public Offering of Common Stock
PRNewswire (Wed, 6-Mar 4:10 PM ET)
REGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM AFFINITY DUCHENNE TRIAL
PRNewswire (Tue, 5-Mar 7:05 AM ET)
PRNewswire (Thu, 29-Feb 4:57 PM ET)
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
Regenxbio trades on the NASDAQ stock market under the symbol RGNX.
As of May 7, 2024, RGNX stock price climbed to $16.96 with 379,645 million shares trading.
RGNX has a beta of 1.73, meaning it tends to be more sensitive to market movements. RGNX has a correlation of 0.14 to the broad based SPY ETF.
RGNX has a market cap of $831.76 million. This is considered a Small Cap stock.
Last quarter Regenxbio reported $22 million in Revenue and -$1.43 earnings per share. This fell short of revenue expectation by $-12 million and missed earnings estimates by -$.16.
In the last 3 years, RGNX stock traded as high as $46.46 and as low as $11.83.
The top ETF exchange traded funds that RGNX belongs to (by Net Assets): IJR, VTI, XBI, VB, IWM.
RGNX stock has underperformed the market in the last year with a return of -10.2%, while SPY returned +27.0%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in RGNX shares. However, RGNX has outperformed the market in the last 3 month and 2 week periods, returning +30.0% and +8.4%, while SPY returned +5.0% and +3.5%, respectively. This indicates RGNX has been having a stronger performance recently.
RGNX support price is $16.21 and resistance is $17.53 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RGNX stock will trade within this expected range on the day.